Abstract: To provide at least one of: a powder composition from which a calcined body with similar processability can be produced without requiring the application of different forming conditions and calcination conditions for each composition; a method for producing the powder composition; a calcined body produced from the powder composition; a method for producing the calcined body; and uses thereof. A powder composition including: two or more types of zirconia in which a lanthanoid rare-earth element is dissolved; a transition metal element other than zirconium and hafnium; and a remainder composed of zirconia stabilized only by one or more selected from the group consisting of yttrium, calcium and magnesium, wherein a different lanthanoid rare-earth element is dissolved in each zirconia in which the lanthanoid rare-earth element is dissolved, and a transition metal element content is 1500 ppm or less.

Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —N? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —N? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

Abstract: The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.

Abstract: The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.

Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X represents —N? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —NH? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —NH? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

Abstract: There is provided a joint structure for a fiber reinforced resin and a metal. In the joint structure, respective end portions of a fiber reinforced plastic and a metallic material are joined to each other. A large number of projections having a height that enables the projections to contact fibers constituting the fiber reinforced plastic are formed on a joint surface of the metallic material serving as a part of a joint surface between the fiber reinforced plastic and the metallic material.

Abstract: The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.

Abstract: There is provided a joint structure for a fiber reinforced resin and a metal. In the structure, multiple single elements are laminated such that the step-shaped structures are superposed in a thickness direction. Each element is constituted by a metallic material including a step-shaped structure having an end portion that gradually becomes thinner towards an end surface thereof so as to form a step-shaped joint surface, and a fiber reinforced plastic laminated such that an end portion thereof covers the step-shaped structure smoothly. A main welding portion is formed on an outer end of the metallic material by welding mating surfaces of adjacent metallic materials. A secondary welding portion is formed on the plastic side of the main welding portion on all the metallic materials by welding them in the thickness direction.

Abstract: There is provided a joint structure for a fiber reinforced resin and a metal. In the joint structure, respective end portions of a fiber reinforced plastic and a metallic material are joined to each other. A large number of projections having a height that enables the projections to contact fibers constituting the fiber reinforced plastic are formed on a joint surface of the metallic material serving as a part of a joint surface between the fiber reinforced plastic and the metallic material.

Abstract: There is provided a joint structure for a fiber reinforced resin and a metal. In the structure, multiple single elements are laminated such that the step-shaped structures are superposed in a thickness direction. Each element is constituted by a metallic material including a step-shaped structure having an end portion that gradually becomes thinner towards an end surface thereof so as to form a step-shaped joint surface, and a fiber reinforced plastic laminated such that an end portion thereof covers the step-shaped structure smoothly. The metallic material and the plastic are adhered, and adjacent elements are joined by superposed surfaces thereof. A main welding portion is formed on an outer end of the metallic material by welding mating surfaces of adjacent metallic materials. A secondary welding portion is formed on the plastic side of the main welding portion on all the metallic materials by welding them in the thickness direction.

Abstract: The present invention provides an excellent antihypertensive medicament. The medicament of the present invention comprises a compound having the general formula (I) and the like: [wherein R1: H, substitutable alkyl, substitutable alkenyl, substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like; R2: H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R3, R4; H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R5, R6: H, substitutable alkyl, substitutable cycloalkyl, substitutable alkoxy or the like; R7, R8: H, substitutable alkyl, substitutable cycloalkyl or the like; X: the formula (II) or the like; A: substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like; Y: a single bond, substitutable alkylene, substitutable alkenylene, —(CH2)a—X1—(CH2)b—(X1: the formula —NH—, —O— or the like; a, b: 0-5) or the like; B: substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like].

Abstract: The present invention provides an excellent antihypertensive medicament. The medicament of the present invention comprises a compound having the general formula (I) and the like: [wherein R1: H, substitutable alkyl, substitutable alkenyl, substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like; R2: H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R3, R4; H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R5, R6: H, substitutable alkyl, substitutable cycloalkyl, substitutable alkoxy or the like; R7, R8: H, substitutable alkyl, substitutable cycloalkyl or the like; X: the formula (II) or the like; A: substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like; Y: a single bond, substitutable alkylene, substitutable alkenylene, —(CH2)a—X1—(CH2)b—(X1: the formula —NH—, —O— or the like; a, b: 0-5) or the like; B: substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like].

Abstract: The present invention provides a decolorized red phosphorus composition capable of inhibiting coloring in dark red peculiar to red phosphorus even when kneaded with a resin or the like, modified red phosphorus used for the decolorized red phosphorus composition and a production method therefor, and a flame-retardant polymer composition using the decolorized red phosphorus composition. The modified red phosphorus includes red phosphorus particles (A) whose surfaces are coated with a modified resin film (F) containing white particles (B) having a whiteness of 70 or more, color particles (C) having a hue H of 30 to 80 in the Munsell color-system hue circle, and a binder resin (D). The decolorized red phosphorus composition includes a mixed powder containing the modified red phosphorus and white particles (B) having a whiteness of 70 or more. The flame-retardant polymer composition contains the decolorized red phosphorus composition and a polymer compound (I).

Abstract: The present invention provides a decolorized red phosphorus composition capable of inhibiting coloring in dark red peculiar to red phosphorus even when kneaded with a resin or the like, modified red phosphorus used for the decolorized red phosphorus composition and a production method therefor, and a flame-retardant polymer composition using the decolorized red phosphorus composition. The modified red phosphorus includes red phosphorus particles (A) whose surfaces are coated with a modified resin film (F) containing white particles (B) having a whiteness of 70 or more, color particles (C) having a hue H of 30 to 80 in the Munsell color-system hue circle, and a binder resin (D). The decolorized red phosphorus composition includes a mixed powder containing the modified red phosphorus and white particles (B) having a whiteness of 70 or more. The flame-retardant polymer composition contains the decolorized red phosphorus composition and a polymer compound (I).

Abstract: An aqueous zinc nitrite solution contains as impurities 10 ppm or less of sodium (Na) and 100 ppm or less of sulfate ions (SO4) when the aqueous solution has a concentration of zinc nitrite [Zn(NO2)2] of 10% by weight in terms of NO2. Also, disclosed is a method for preparing an aqueous zinc nitrite solution, including a first step of reacting zinc sulfate with calcium nitrite to form an aqueous zinc nitrite solution and a second step of purifying the aqueous zinc nitrite solution.

Abstract: This invention provides a metal surface-treating method which comprises a chemical conversion step of dipping a substrate in an acidic aqueous zinc phosphate solution, and using an aqueous zinc nitrite solution as an accelerator, said aqueous zinc nitrite solution being substantially free of calcium ion and containing 0 to 6500 ppm of sodium ion and 0 to 20 ppm of sulfate ion in case of assuming the concentration of zinc nitrite [Zn(NO2)2] therein to be 10 weight % as NO2.

Abstract: This invention provides a metal surface-treating method